Labtician Launches Lab TRIACTIV Artificial Tears

Labtician Ophthalmics has officially announced the commercial launch of Lab TRIACTIV, a next-generation artificial tear formulated to deliver comprehensive and long-lasting dry eye relief. The product is now available in the Canadian market and is positioned to raise the standard of care in dry eye management.

Advanced Cationic Liposomal Technology for Triple-Layer Tear Film Support

Lab TRIACTIV leverages advanced cationic liposomal technology to target all three layers of the tear film—lipid, aqueous, and mucin. According to the company, this enables the formulation to provide:

• Sustained hydration

• Enhanced ocular surface protection

• Long-lasting comfort

• Fewer daily applications

The formulation is also preservative-free and compatible with contact lenses, addressing key concerns for chronic dry eye patients.

Key Ingredients Optimizing Tear Film Stability

Labtician Ophthalmics highlighted the active ingredients in Lab TRIACTIV that contribute to tear film stability and ocular health, including:

• Stearylamine

• Cross-linked sodium hyaluronate

• Trehalose

• Phospholipids

Together, these components work synergistically to improve lubrication, reduce oxidative stress, and enhance tear film retention on the ocular surface.

Commitment to Visual Health and Innovation

“We are incredibly proud to introduce Lab TRIACTIV to the Canadian market, reinforcing our commitment to advancing the Visual Health of Patients with solutions that make a real difference,” said Polydor Strouthos, President of Labtician Ophthalmics.
“Lab TRIACTIV supports our commitment to redefining industry standards. We are excited to set a new benchmark in dry eye care.”